Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis

被引:0
|
作者
Spadaro, A
Taccari, E
Riccieri, V
Sensi, F
Scavalli, AS
Zoppini, A
机构
来源
REVUE DU RHUMATISME | 1997年 / 64卷 / 02期
关键词
interleukin-2; interleukin-6; rheumatoid factor; methotrexate; rheumatoid arthritis;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied the effect of a 6-month treatment with low-dose MTX in 22 RA patients, with the purpose of investigating the relationship of sIL-2R and IL-6 serum chancres with those of class specific RFs. The patients with RA had higher serum levels of sIL-2R (p<0.00001) and IL-6 (p<0.0005) than healthy volunteers. We found that the levels of IgM-RF (p<0.0004), IgA-RF (p<0.002), IgG-RF (p<0.025), sIL-2R (p<0.017) and IL-6 (p<0.044), as well as the main clinical and laboratory variables, were significantly reduced in RA patients treated with low dose MTX for six months. The changes from baseline of IgM-RF correlated with those of IL-6 (p<0.023), suggesting that MTX may affect IL-6 and IgM-RF production in part by a common mechanism. In conclusion our results show that there is a relationship between IL-6 and IgM-RF changes from baseline during MTX therapy, but the hypothesis of a link between the effects of this drug on cytokine network and RF production needs further investigation.
引用
收藏
页码:89 / 94
页数:6
相关论文
共 50 条
  • [21] Interleukin-6 As a Biomarker for the Clinical and Radiological Effectiveness of Methotrexate in Rheumatoid Arthritis.
    Nishina, Naoshi
    Kameda, Hideto
    Kaneko, Yuko
    Kuwana, Masataka
    Takeuchi, Tsutomu
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S896 - S897
  • [22] THE EFFECTS OF METHOTREXATE ON SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN RHEUMATOID-ARTHRITIS - COMMENT
    CRILLY, A
    MADHOK, R
    ARTHRITIS AND RHEUMATISM, 1994, 37 (04): : 597 - 598
  • [23] THE EFFECTS OF METHOTREXATE ON SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN RHEUMATOID-ARTHRITIS - REPLY
    BARRERA, P
    BOERBOOMS, AMT
    VANDEPUTTE, LBA
    VANDERMEER, JWM
    ARTHRITIS AND RHEUMATISM, 1994, 37 (04): : 598 - 599
  • [24] TREATMENT OF CHRONIC RHEUMATOID-ARTHRITIS WITH LOW-DOSE METHOTREXATE
    KARGER, T
    RAU, R
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1988, 113 (21) : 839 - 846
  • [25] INFLUENCE OF CORTICOSTEROID PULSE THERAPY ON THE SERUM LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR, INTERLEUKIN-6 AND INTERLEUKIN-8 IN PATIENTS WITH RHEUMATOID-ARTHRITIS
    VANDENBRINK, HR
    VANWIJK, MJG
    GEERTZEN, RGM
    BIJLSMA, JWJ
    JOURNAL OF RHEUMATOLOGY, 1994, 21 (03) : 430 - 434
  • [26] USE OF INTERLEUKIN-6 INHIBITOR IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ELDERLY PATIENTS
    Shilova, L.
    Spitsina, S.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S292 - S293
  • [27] Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
    Patel, Aarat M.
    Moreland, Larry W.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 263 - 278
  • [28] Relationship of Interleukin-12 and Interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus
    A. Spadaro
    R. Scrivo
    M. Bombardieri
    V. Riccieri
    T. Rinaldi
    E. Taccari
    G. Valesini
    Clinical Rheumatology, 2003, 22 : 107 - 111
  • [29] BASELINE SOLUBLE INTERLEUKIN-6 RECEPTOR LEVELS PREDICT THE CLINICAL EFFECTIVENESS OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Nishina, N.
    Kikuchi, J.
    Hashizume, M.
    Yoshimoto, K.
    Kameda, H.
    Takeuchi, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 369 - 369
  • [30] Relationship of Interleukin-12 and Interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus
    Spadaro, A
    Scrivo, R
    Bombardieri, M
    Riccieri, V
    Rinaldi, T
    Taccari, E
    Valesini, G
    CLINICAL RHEUMATOLOGY, 2003, 22 (02) : 107 - 111